drugset / Trial / NCT01077908
Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study
Phase 3
Completed
89 enrolled
Cell Medica Ltd
BioAnaLab · collabCommitum AB · collabEMAS Pharma · collabWellcome Trust · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the potential clinical benefit of prophylactic cytomegalovirus (CMV)-specific adoptive cellular therapy following T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) for reducing recurrent CMV reactivation.
Timeline
- Start
- 2008-07
- Primary completion
- 2014-09
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TROCULEUCEL | Cell therapy | — | — |
| Background | Foscarnet | Small molecule | 90 mg/kg | Intravenous |
| Background | Ganciclovir | Small molecule | 5 mg/kg | Intravenous |
| Background | Valganciclovir | Small molecule | 900 mg | Oral |